A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease

Exclusion Criteria

• •1. Has liver steatosis due to other definitive causes, such as alcoholic liver disease, drug-induced liver injury, viral hepatitis infections (e.g., hepatitis B, hepatitis C, etc.);
• •2. Has other serious liver diseases, such as autoimmune liver diseases, primary biliary cholangitis, Wilson's disease, etc.;
• •3. Has severe dysfunction of major organs such as the heart, kidneys, lungs, etc., such as severe heart failure (NYHA functional classification III or above), renal failure (glomerular filtration rate eGFR \< 30 mL/min/1.73m²), acute exacerbation of chronic obstructive pulmonary disease, etc.;
• •4. Has other serious systemic diseases, such as malignant tumors, active systemic lupus erythematosus, etc.;
• •5. Known allergy or intolerance to any component of the study medication;
• •6. Has participated in another clinical trial within the last three months;
• •7. Pregnant women, lactating women, or women of childbearing age who refuse to use effective contraception during the trial;
• •8. Has severe mental illness or behavioral disorders that may affect adherence to the study protocol;
• •9. Other conditions that the researcher considers unsuitable for participation in this study.